Federal health regulators declined to approve MDMA for PTSD therapy, a setback for groups advocating for psychedelic substances in mental health treatment.
FDA cited 'significant limitations' in Lykos Therapeutics' data for MDMA, preventing approval for PTSD; additional study requested.
Collection
[
|
...
]